Instil Bio (TIL) Competitors $28.78 -2.99 (-9.41%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TIL vs. RLAY, ETNB, IMTX, ERAS, ABUS, IMNM, REPL, CRMD, PHVS, and ANNXShould you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Relay Therapeutics (RLAY), 89bio (ETNB), Immatics (IMTX), Erasca (ERAS), Arbutus Biopharma (ABUS), Immunome (IMNM), Replimune Group (REPL), CorMedix (CRMD), Pharvaris (PHVS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Instil Bio vs. Relay Therapeutics 89bio Immatics Erasca Arbutus Biopharma Immunome Replimune Group CorMedix Pharvaris Annexon Instil Bio (NASDAQ:TIL) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Do institutionals & insiders hold more shares of TIL or RLAY? 60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 46.5% of Instil Bio shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend TIL or RLAY? Instil Bio currently has a consensus target price of $110.00, indicating a potential upside of 282.21%. Relay Therapeutics has a consensus target price of $21.11, indicating a potential upside of 261.49%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Relay Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has higher earnings and valuation, TIL or RLAY? Instil Bio has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$156.09M-$18.42-1.56Relay Therapeutics$25.55M30.60-$341.97M-$2.52-2.32 Does the media prefer TIL or RLAY? In the previous week, Relay Therapeutics had 8 more articles in the media than Instil Bio. MarketBeat recorded 9 mentions for Relay Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.76 beat Relay Therapeutics' score of -0.01 indicating that Instil Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Instil Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in TIL or RLAY? Instil Bio received 44 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 67.50% of users gave Relay Therapeutics an outperform vote while only 50.52% of users gave Instil Bio an outperform vote. CompanyUnderperformOutperformInstil BioOutperform Votes9850.52% Underperform Votes9649.48% Relay TherapeuticsOutperform Votes5467.50% Underperform Votes2632.50% Is TIL or RLAY more profitable? Relay Therapeutics' return on equity of -43.66% beat Instil Bio's return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -55.57% -37.76% Relay Therapeutics N/A -43.66%-38.38% Which has more risk & volatility, TIL or RLAY? Instil Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. SummaryInstil Bio and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Instil Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TIL vs. The Competition Export to ExcelMetricInstil BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.07M$3.14B$5.39B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-1.5612.18113.8115.12Price / SalesN/A332.371,483.2593.03Price / CashN/A148.6339.6434.05Price / Book0.834.024.665.02Net Income-$156.09M-$42.25M$119.06M$225.46M7 Day Performance-7.34%8.08%0.79%0.37%1 Month Performance-50.38%8.72%5.65%3.57%1 Year Performance273.77%32.11%36.76%29.42% Instil Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TILInstil Bio3.1455 of 5 stars$28.78-9.4%$110.00+282.2%+293.2%$187.07MN/A-1.5649Gap DownRLAYRelay Therapeutics3.2138 of 5 stars$6.02-2.7%$21.11+250.7%-14.5%$799.11M$35.21M-2.39304Upcoming EarningsNews CoverageETNB89bio1.7435 of 5 stars$7.87+1.3%$31.00+293.9%+15.5%$798.88MN/A-3.9940News CoverageIMTXImmatics1.5725 of 5 stars$9.26-2.8%$17.50+89.0%+19.6%$783.93M$70.87M-10.40260Short Interest ↑ERASErasca2.6092 of 5 stars$2.64+2.3%$6.10+131.1%+19.8%$754.29MN/A-2.87126Gap UpABUSArbutus Biopharma2.2958 of 5 stars$3.97-2.0%$5.25+32.2%+115.2%$749.21M$10.06M-8.8273Upcoming EarningsIMNMImmunome2.4993 of 5 stars$12.11+0.8%$29.00+139.5%+35.2%$727.21M$14.02M-1.5740Short Interest ↓Gap UpREPLReplimune Group3.6999 of 5 stars$11.73-1.9%$16.80+43.2%-16.7%$720.40MN/A-3.59210Upcoming EarningsCRMDCorMedix2.6988 of 5 stars$13.04+4.6%$13.60+4.3%+193.8%$716.67M$806,119.00-14.0230Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumePHVSPharvaris2.058 of 5 stars$21.71+1.8%$33.60+54.8%+42.8%$691.25MN/A-8.4130Upcoming EarningsANNXAnnexon1.4361 of 5 stars$7.40-0.5%$15.80+113.5%+203.3%$683.86MN/A-6.0260 Related Companies and Tools Related Companies RLAY Competitors ETNB Competitors IMTX Competitors ERAS Competitors ABUS Competitors IMNM Competitors REPL Competitors CRMD Competitors PHVS Competitors ANNX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TIL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.